UBS analyst Jay Sole downgrades Victoria’s Secret (NYSE:VSCO) from Neutral to Sell.
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and lowers the price target from $16 to $15.